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Various drug delivery approaches have been explored for successful delivery of
drugs to the target site. However, the oral route of administration is considered to be the
529
Acta Pharm. 62 (2012) 529–545 Original research paper
DOI: 10.2478/v10007-012-0034-x
Eudragit S-100 coated sodium alginate microspheres









Accepted September 4, 2012
The aim of the study was to prepare site specific drug delivery
of naproxen sodium using sodium alginate and Eudragit S-100
as a mucoadhesive and pH-sensitive polymer, respectively. Core
microspheres of alginate were prepared by a modified emulsifi-
cation method followed by cross-linking with CaCl2, which was
further coated with the pH dependent polymer Eudragit S-100
(2.5 or 5 %) to prevent drug release in the upper gastrointestinal
environment. Microspheres were characterized by FT-IR spectro-
scopy, X-ray diffraction, differential scanning calorimetry and
evaluated by scanning electron microscopy, particle size analy-
sis, drug loading efficiency, in vitro mucoadhesive time study
and in vitro drug release study in different simulated gastric flu-
ids. Stability studies of the optimized formulation were carried
out for 6 months. SEM images revealed that the surface morpho-
logy was rough and smooth for core and coated microspheres,
respectively. Core microspheres showed better mucoadhesion
compared to coated microspheres when applied to the mucosal
surface of freshly excised goat colon. The optimized batch of co-
re microspheres and coated microspheres exhibited 98.42 ± 0.96
and 95.58 ± 0.74 % drug release, respectively. Drug release from
all sodium alginate microsphere formulations followed Higuchi
kinetics. Moreover, drug release from Eudragit S-100 coated mi-
crospheres followed the Korsmeyer-Peppas equation with a
Fickian kinetics mechanism. Stability study suggested that the
degradation rate constant of microspheres was minimal, indicat-
ing 2 years shelf life of the formulation.
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xen sodium, sodium alginate
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most convenient and preferred route for a sustained as well as controlled drug delivery
system (1).
Various drug delivery strategies have been employed to trigger the release of drugs
to the large intestine; however, they do not reach the site of action in appropriate con-
centrations. Thus, to ensure an effective and safe therapy for the large bowel diseases,
the colon specific drug delivery system is considered to be the preferable approach (2).
Targeting of drugs to the colon offers several potential therapeutic advantages, like
increasing the systemic absorption of poorly absorbed drugs and effective treatment of the
colonic diseases such as amoebiasis, ulcerative colitis, Crohn’s disease, colorectal cancer,
etc. This delivery system can be also used in certain conditions where drugs should be de-
livered after a lag time, like in chronopharmacotherapy of diseases showing Circadian
rhythms in their pathophysiology (3). Several available approaches for targeting the drug
selectively to the colon include pH sensitive polymers, time dependent dosage forms, use
of carriers degraded by enzymes produced by colonic bacteria, prodrug based ap-
proaches, bioadhesive and osmotically controlled drug delivery systems (4). Colon spe-
cific drug delivery (CDDS) microspheres are advantageous owing to the fact that, in com-
parison with conventional dosage forms, CDDS microspheres provide a more consistent
and reproducible transit through the gastrointestinal tract (GIT). Moreover, they also pro-
vide more uniform drug dispersion in the GI tract, which results in more homogeneous
drug absorption. This helps in predicting gastric emptying, increases colon residence time,
decreases local irritation (5).
The third most common deadly cancer in the world is colorectal cancer. Epidemio-
logical investigations and clinical trials done in patients with hereditary colon cancer
and familial adenomatous polyposis (FAP) highlight the importance of nonsteroidal
anti-inflammatory drugs (NSAIDs), which act as COX inhibitors and hence, due to their
mode of action similar to that of anticancer drugs, halt the development of colon cancer-
ous cell growth (6).
Naproxen [(S)-2-(6-methoxynaphthalen-2-yl)propanoic acid], is a non selective COX
inhibitor widely used as an analgesic in the treatment of rheumatoid arthritis and colitis.
It can be used in FAP and in colon cancers due to its inhibitory action on COX-2 en-
zymes (7, 8). Moreover, because of the same mode of action, it shows synergistic action
with that of anticancer drugs. Sodium alginate is a sodium salt of alginic acid and is a
natural polysaccharide derived from brown seaweeds. It is composed of b-D-mannuro-
nic acid and a-L-guluronic acid. It is biocompatible, biodegradable, non-toxic and shows
mucoadhesive properties as well. Due to its mucoadhesion nature, its residence time in
the colon can be increased, which subsequently results in maximum bioavailability (9).
Eudragit belongs to another class of biocompatible polymers. Eudragit S-100 is a pH-
-sensitive anionic copolymer consisting of methacrylic acid and methacrylate in the ratio
1:2. It does not degrade below pH 7. Eudragit S-100 has been used to prevent drug re-
lease from microspheres in the small intestine (10).
Taking the above information into account, a study was designed for the prepara-
tion and characterization of naproxen sodium, as a non-selective COX inhibitor, incorpo-
rated in sodium alginate and Eudragit S-100 coated microspheres for the colon drug de-
livery system.
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EXPERIMENTAL
Materials
Naproxen sodium and Eudragit S-100 were procured as gift samples from Micro
Labs Pvt. Ltd. (Bangalore, India) and Evonik Industries (Mumbai, India), respectively.
Sodium alginate and Span 80 were received from Loba Chemie Pvt. Ltd. (Mumbai, In-
dia). All polymers and chemicals used were of analytical grade.
Methods
Preparation of Eudragit S-100 coated sodium alginate microspheres involved two
steps, i.e., step I and step II. In step I, sodium alginate microspheres were prepared and
in step II, optimized formulations from step I were coated with Eudragit S-100 polymer
to prevent the release of drug content in the stomach and small intestine. Procedures of
step I and step II were as follows (11, 12).
Preparation of sodium alginate microspheres
An emulsification method was used for the preparation of alginate microspheres,
followed by cross-linking with calcium chloride (5 %, m/V, in IPA). Core microspheres
were prepared with different drug polymer ratios (NM1 to NM7), as shown in Table I.
A weighed amount of sodium alginate was dissolved in warm distilled water and the
drug was then dispersed in this aqueous solution. Subsequently, the dispersion was
emulsified in light liquid paraffin containing Span 80 (2 %, V/V) with the help of a me-
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NM1 1 : 2 314.68 72.3 ± 1.07
NM2 1 : 3 317.09 75.9 ± 1.51b
NM3 1 : 4 426.32 76.6 ± 1.02b
NM4 1 : 5 444.08 78.1 ± 1.30c
NM5 1 : 6 450.41 87.6 ± 1.22c
NM6 1 : 7 478.65 74.9 ± 2.38
NM7 1 : 8 484.35 76.2 ± 1.35b
Coated formulations core : coat ratio – –
NM8 1 : 2.5 454.26 92.4 ± 1.16c
NM9 1 : 5 459.28 86.8 ± 1.07c
a Data are expressed as mean ± SD (n = 3).
b Statistically significant difference at p < 0.05.
c Statistically significant difference at p < 0.001 from control (NM 1) as determined by one-way
ANOVA, followed by Dunnett’s test.
chanical stirrer (propeller type) (Remi Instrument Ltd, Mumbai, India) at 400 rpm for 1 h.
A solution of calcium chloride (5 %, m/V in IPA) was added dropwise to the emulsion at
a rate of 1 mL min–1 to harden the formed microspheres and stirring was continued for
another 20 min to ensure efficient cross-linking. Microspheres were collected by filtra-
tion and washed three times with petroleum ether to remove the residual liquid paraf-
fin. Microspheres were frozen for 10 h and then kept in vacuum desiccators for 12 h.
Preparation of Eudragit S-100 coated microspheres
The optimized batch (NM5) of sodium alginate microspheres was coated with two
different concentrations of Eudragit S-100, as shown in Table I. Core microspheres were
dispersed in an Eudragit S-100 solution (5 %, m/V) in acetone and isopropyl alcohol so-
lution at room temperature, followed by emulsification in light liquid paraffin contain-
ing Span 80 (2 %, V/V) in a beaker with the help of a mechanical stirrer (propeller type)
at 400 rpm. The system was agitated for 3 h at room temperature to allow solvent evapo-
ration. Finally, encapsulated microspheres (NM8, NM9) were filtered and washed with
petroleum ether to remove the traces of oil and dried in a vacuum desiccator for 24 h.
Characterization of naproxen sodium microspheres
FT-IR spectroscopy. – The FT-IR spectra of pure drug (naproxen sodium), sodium
alginate, Eudragit S-100 and coated microsphere were recorded with an FTIR spectro-
photometer (Mode spectrum RX 1, Perkin Elmer, England) using the potassium bromide
disk method, in the range of 4000–400 cm–1.
X-ray diffraction analysis (XRD). – XRD analysis investigates the effect of microen-
capsulation on the crystallinity of the drug as well as drug-loaded microspheres. X-ray
diffractograms of naproxen sodium, sodium alginate, Eudragit S-100, physical mixture
(naproxen sodium and sodium alginate), core microspheres, physical mixture (naproxen
sodium, sodium alginate and Eudragit S-100) and coated microsphere were recorded
with an X-ray diffractometer (XPERT-PRO, PAN analytical, The Netherlands) using the
PRS measurement program using Ni-filtered, CuKa radiation with a voltage of 45 kV
and a current of 40 mA. The instrument was operated at continuous scanning speed
over 2q range of 5 to 49°.
Differential scanning calorimetry (DSC). – Thermal analyses of naproxen sodium, so-
dium alginate, Eudragit S-100, mixture of drug and sodium alginate, core microspheres,
physical mixture (naproxen sodium and sodium alginate and Eudragit S-100) and coa-
ted microspheres were performed using a differential scanning calorimeter (Shimadzu,
DSC 60, Japan) to study the thermal behaviour of samples. All samples were heated in
hermetically sealed aluminium pans at a constant scanning rate of 10 °C min–1 from 40
to 260 °C under air atmosphere (50 mL min–1) by applying the minimum possible pres-
sure. An empty aluminium pan was used as reference.
Surface morphology. – Shape and surface morphology of both core and coated micro-
spheres were observed using scanning electron microscopy (JSM 6100 Jeol, Japan). Sam-
ples mounted on an aluminium stub were sputter coated with gold under reduced pres-
sure and a thick gold coat was applied using a JFC 1100 (Japan) sputter coater. The
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sample assembly was placed in the microscope and vacuum was applied. The micro-
spheres were observed under SEM.
Particle size analysis. – The particle size distribution of core as well as coated micro-
spheres was determined. Freeze-dried microspheres were dispersed in 20 mL isopropyl
alcohol and sonicated for 5 min to bring about disaggregation of the microspheres. Mi-
crospheres were sized using a particle size analyser (Malvern Instruments, Mastersizer
2000, UK).
Drug loading and drug loading efficiency. – To determine the drug content in micro-
spheres, an accurately weighed quantity of microspheres equivalent to 20 mg of the drug
was crushed and dissolved in 100 mL phosphate buffer pH 7.4 in a volumetric flask and
stirred for 12 h (13, 14). After stirring, the solution was filtered through Whatman filter
paper, the filtrate was diluted using phosphate buffer pH 7.4 and absorbance was mea-
sured for the determination of unentrapped drug at 272 nm using a UV/Visible spec-
trophotometer (Systronics, Mumbai, India). Observations were taken in triplicate to cal-
culate drug loading and drug loading efficiency.
In vitro drug release study
Core microspheres. – Microspheres equivalent to 2 mg of naproxen sodium were
weighed accurately and suspended in 20 mL of phosphate buffer pH 7.4 containing 1 %
(m/V) sodium dodecyl sulphate (SDS) to maintain the sink condition for the drug. The
mixture was stirred at 37 °C using a magnetic stirrer at a stirring speed of 50 rpm for 3 h.
At specified time intervals, samples were withdrawn (2 mL) and replaced with the same
volume of fresh media. The withdrawn samples were centrifuged at 3000 rpm for 10 min
and were then filtered and diluted with phosphate buffer pH 7.4. The drug content was
measured by taking supernatant absorbance using a UV/Visible spectrophotometer
(Systronics, Mumbai, India).
Coated microspheres. – Microspheres equivalent to 2 mg of naproxen sodium were
weighed accurately and suspended in 20 mL of 0.01 mol L–1 HCl. The mixture was stir-
red on a magnetic stirrer at 37 °C at a stirring speed of 50 rpm for 2 h. Samples were
withdrawn at specified intervals and an equivalent amount of fresh medium was added.
Collected samples were centrifuged, filtered through a membrane filter (0.45 µm) and
analysed for drug content using a UV/Visible spectrophotometer.
The coated microspheres equivalent to 2 mg of the drug were placed in 20 mL of
phosphate buffer pH 6.8 containing 1 % (m/V) SDS (to maintain the sink condition) and
stirred magnetically at 50 rpm. The pH of the medium was maintained at 6.8 for 2 h and
then it was slowly increased to 7.4 by the addition of disodium hydrogen phosphate.
Two millilitres of aliquots was withdrawn at predetermined intervals with replacement
of the same volume of fresh medium. The samples were centrifuged, filtered and ana-
lysed for drug content at 272 nm using spectrophotometry.
Drug release kinetics. – The in vitro drug release patterns were fitted to various re-
lease kinetic models, zero order, first order, Higuchi model and Korsmeyer-Peppas po-
wer law equation.
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Statistical analysis
The in vitro drug release profiles from the microspheres were compared by statisti-
cal analysis using one-way ANOVA, followed by Dunnett’s test. A difference was con-
sidered statistically significant at a p-value less than 0.05.
In vitro mucoadhesion study
The in vitro mucoadhesion study of the microspheres was carried out using the in
vitro wash-off test reported by Lehr et al. (15). Proximal portion of a freshly slaughtered
goat’s large intestine was cut to expose the mucosal surface and washed with distilled
water and phosphate buffer pH 7.4. A 2×2 cm serosal side was attached via a thread onto
a glass slide. Coated microspheres (5 mg) were spread over the exposed mucosal surface
and rinsed with phosphate buffer pH 7.4. The assembly was then kept in a humidity
chamber (Thermotech, India, Model TH-7004) at 37 °C/90 % RH for 30 min. In the above
pretreatment, Eudragit S-100 coat got dissolved, exposing sodium alginate core
microspheres. Mucoadhesiveness of the microspheres was measured by mounting the
complete assembly onto a disintegration apparatus (EI Products, Panchkula, India) with
the help of a clamp and a thread. The apparatus was operated in such a manner that the
tissue was allowed to move in reciprocating motion at a frequency of 28–32 cycles per
minute while immersed in phosphate buffer pH 7.4 contained in a 1000 mL beaker. The
time taken by the tissue to completely wash off the microsphere was considered the mu-
coadhesion time.
Stability studies
Three different batches of all formulations were subjected to stability studies accor-
ding to the International Conference of Harmonization (ICH) guidelines. Uncoated and
coated microspheres were put ino hard gelatin capsules wrapped in aluminium foil lami-
nated on the inside with polyethylene. The samples were kept at room temperature and
under accelerated conditions in a stability chamber (Stability Oven, Nirmal Instruments,
India). Real time stability studies were performed by periodical testing of the drug con-
tent at intervals of 0, 30, 90 and 180 days during 6 months.
RESULTS AND DISCUSSION
FT-IR spectra of naproxen sodium, sodium alginate, Eudragit S-100, and coated mi-
crospheres are depicted in Fig. 1. The drug sample showed characteristic functional group
peaks at 1252 (acid C-O), 1583 (COO–), 1631 (C-C aromatic), 2840 cm–1 (C-H aliphatic).
Coated microspheres showed characteristic peaks at 1607 (sodium alginate), 3504 and
2953 (naproxen sodium), 1606 (sodium alginate), 1731 (Eudragit S-100), 1586 and 1244
cm–1 (naproxen sodium). Finally, the FT-IR study concluded that major characteristic
peaks of naproxen sodium were found in entire coated microspheres, which confirms
the presence of the drug in the polymer without any interaction.
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The XRD study suggested that the X-ray diffractogram (Fig. 2) of naproxen sodium
indicated the presence of crystalline material with sharp principle peaks at 13.50 and
17.45°, whereas both polymers, sodium alginate and Eudragit S-100, were found to be
amorphous in nature. The X-ray diffractogram of core and coated microspheres of na-
proxen sodium showed an amorphous material devoid of any crystallinity due to the di-
lution effect of the amorphous polymers.
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Fig. 1. Fourier transform infrared spectra of naproxen sodium, sodium alginate, Eudragit S-100, and
coated microspheres (NM9).
According to the differential scanning calorimetry thermograms (Fig. 3), naproxen
sodium showed a sharp endothermic peak at 257.50 °C corresponding to its melting
point in the crystalline form. DSC scans of sodium alginate under air depict a wide en-
dothermic peak at 100.00 °C, which was attributed to water evaporation. A maximum
exothermic peak was shown at 263.66 °C (16, 17). Eudragit S-100 exhibited two endo-
thermic peaks at 82.51 and 230.01 °C. DSC scan of the uncoated microsphere of sodium
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Fig. 2. X-ray diffraction spectra of: a) naproxen sodium, b) sodium alginate powder, c) Eudragit
S-100, d) physical mixture of drug and sodium alginate, e) core microspheres, f) physical mixture
(drug, sodium alginate and Eudragit S-100) and g) coated microsphere.
alginate showed a sharp endothermic peak around 252.00 °C and a broad exothermic
peak at 119.00 °C. In the physical mixture, the presence of Eudragit S-100, interaction be-
tween Eudragit S-100 and sodium alginate (disappearance of sodium alginate exother-
mic peak at 283.00 °C) can be proposed. The endothermic peak of naproxen sodium at
257.00 shifted to 249.00 °C in the physical mixture with Eudragit S-100 and peak inten-
sity was also reduced due to its low percentage in the physical mixture (2 %, m/m). How-
ever, thermograms of coated microspheres suggest that a depressed, broad endothermic
peak at 93.00 °C could be a contribution of the dilution effect of amorphous polymer.
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Fig. 3. DSC thermograms of: a) naproxen sodium, b) sodium alginate, c) Eudragit S100, d) physical
mixture (drug and sodium alginate), e) core microspheres, f) physical mixture (drug, sodium
alginate and Eudragit S-100) and g) coated microspheres.
On the basis of scanning electron microscopy (Fig. 4) of core microspheres, it was
concluded that the microspheres formed were spherical in shape for both core and coa-
ted microspheres due to surface attached crystals of the drug. In the case of core micro-
spheres, they were discrete, having a rough surface with an increased number of pores
causing rapid release of the drug in the medium. On the other hand, SEM images of coa-
ted naproxen sodium microspheres showed them to have a smooth surface and a smal-
ler number of pores due to coating, which led to a decrease in the drug release rate from
microspheres, as shown in Fig. 6.
The effect of polymer concentration on the particle size of microspheres was studied
and is given in Table I. As the concentration of polymer increases in core microspheres,
it leads to an increase in viscosity and thus to an increase in the emulsion droplet size,
and finally to higher microsphere size. In the case of coated microspheres, particle size
again increases with increased concentration (Eudragit S-100) and the coating thickness
over the microspheres increases, which results in larger size.
The drug loading efficiency values for all formulations are given in Table I. The per-
centage drug entrapment was found to be in the range from 75.95 to 87.65 % for sodium
alginate microspheres (core microspheres). The highest drug loading efficiency was
found to be 87.6 % for NM5 at the drug/polymer ratio 1:6. ANOVA results reveal that a
significant (p < 0.01, Table 1) effect on drug entrapment efficiency (%) of core microsphe-
res was observed at varying polymer concentrations, except for formulation NM6. How-
ever, a significant effect (p < 0.001) on entrapment efficiency of coated microspheres
(NM8 and NM9) in comparison with core microspheres (NM1) was also shown. The re-
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Fig. 4. SEM micrographs of a) core microspheres of formulation NM3 and b) Eudragit S-100
coated microspheres of batch NM8.
sults revealed that as the concentration of polymer increased, the drug loading efficiency
also increased, except for formulations NM6 and NM7. This decrease in drug loading ef-
ficiency effect may be due to the contribution of the saturation concentration effect of
the polymer at a certain level, which resulted in reduced drug incorporating efficiency
in the microspheres (18).
On the other hand, coated microspheres showed drug loading efficiency of 92.4 and
86.8 % for formulations NM8 and NM9, respectively. The drug loading efficiency of
coated microspheres was higher compared to core microspheres, which may be attribu-
ted to the finding that due to the coating on microspheres, the integrity of core micro-
spheres was retained, which caused less leaching of the drug from core microspheres
and led to higher drug loading efficiency (12).
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Fig. 5. In vitro release profile of sodium alginate core microspheres. Data are expressed as mean
± SD (n = 3).
Fig. 6. In vitro release profile of Eudragit S-100 coated microspheres in different media. Data are ex-
pressed as mean ± SD (n = 3). * Statistically significant difference at p < 0.001. ** Statistically signifi-
cant difference at p < 0.0001 from NM9 as determined by Student’s t-test.
The in vitro release study of naproxen sodium tablets in different dissolution media,
i.e., pH 1.2, phosphate buffer, pH 6.8 and phosphate buffer pH 7.4, revealed that drug re-
lease from the tablet was observed faster in pH 1.2, followed by pH 6.8 and pH 7.4. The
naproxen sodium tablet showed total release within 7 h. However, the release from so-
dium alginate microspheres was slow and constant compared to naproxen sodium tab-
lets. Optimized formulation of sodium alginate microspheres showed maximal drug re-
lease of 98.42 % in 10 h. It also resulted in lower release in pH 1.2 and pH 6.8 compared
to the naproxen sodium tablet. Therefore, these findings suggest that sodium alginate
showed complete drug release within 10 h, which is insufficient for targeting the drug to
the colon. Hence, this indicates that there is a need for enteric coating, i.e., Eudragit S-100
coating, on sodium alginate microspheres to target drug release to the colon.
The in vitro drug release profile of different core microsphere formulations contain-
ing different drug/sodium alginate ratios is shown in Fig. 5. With an increase in poly-
mer concentration, the drug release rate of microspheres was found to decrease, which
might be due to the formation of a rigid polymer matrix at higher polymer concentra-
tion in the microspheres. This result may be due to the increase in sodium alginate con-
centration leading to the formation of relatively strong walls of microspheres, and
thereby retardation of drug release. Further, the increase in polymer chain entanglement
and subsequent low dissolution of the polymer might be responsible for the retardation
of drug release from the microspheres (19). Core microsphere formulation NM5 showed
maximal drug release at pH 7.4 (98.42 %) compared to other core microsphere formula-
tions. On the basis of drug release, NM5 (drug/polymer ratio 1:6) was selected for the
preparation of Eudragit S-100 coated microspheres.
The in vitro release study (Fig. 6) of Eudragit S-100 coated microspheres revealed
that drug release could be successfully retarded in an acidic environment, i.e., pH 1.2.
Drug release at pH 6.8 was found to be negligible due to Eudragit S-100 (as enteric co-
polymer methacrylic acid-methyl methacrylate) soluble at pH > 7. In release medium
pH 7.4, the NM9 microsphere showed about 4 % drug release over a period of 2 h com-
pared to 7 % drug release of NM8. The amount of coating in NM9 was larger, resulting
in more time to dissolve and release the drug from the microsphere. Formulation NM8
showed a statistically significant (p < 0.001) difference in drug release characteristics
compared to formulation NM9, as determined by Student’s t-test. However, formulation
NM8 having a lower concentration of Eudragit S-100 coating (2.5 %, m/V) showed
higher drug release, i.e., 95.6 % within a period of 5 h at pH 7.4, whereas formulation
NM9 showed lower drug release (89.5 %) over 5 h at pH 7.4 due to thicker coating. It
was observed in a previous study that the in vitro drug release of naproxen coated with
Eudragit L-100 showed approximately 90 % drug release, which is lower compared to
the present study (20).
The percentage drug release profiles obtained from in vitro release experiments were
subjected to different kinetics models to find the drug release mechanism and kinetics.
The zero order (cumulative amount of drug release vs. time), first order (log cumulative
percentage of drug remaining vs. time) (21), and Higuchi kinetics (cumulative percent-
age of drug release vs. square root of time) (22) were used as the kinetics model. Also,
the Korsmeyer-Peppas equation (log cumulative percentage of drug released vs. log ti-
me) (23) was used for the first 60 % of drug released from the microsphere. Regression
coefficients (R2) for all microsphere formulations using different kinetics equations are
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listed in Table II. The table data reveal that in vitro release from the core microsphere (so-
dium alginate microsphere) was better explained by the Higuchi equation, since the
plots provide the highest linearity. For all sodium alginate microspheres, the n value as
per Korsmeyer-Peppas model was found to be between 0.45 and 0.89, indicating anoma-
lous release behaviour of the drug, i.e., both diffusion and dissolution of the hydrated
polymer matrix might be responsible for drug release from the microsphere (24, 25).
Coated microspheres followed Fickian kinetics with the value n < 0.45 as per the Kors-
meyer-Peppas model. This could be due to relaxation of the polymer matrix, followed
by the diffusion matrix.
Determinations of in vitro mucoadhesion suggest that complete detachment of the
microsphere from mucosal tissue took 90 min, indicating good mucoadhesive properties
of sodium alginate. To provide better mucoadhesion, the polymer should show the pres-
ence of a strong hydrogen bonding group like –OH, –COOH and strong anionic charges
spreading on the mucus (26).
Sodium alginate is in the first-generation mucoadhesive polymer group, which con-
tains higher hydrogen bond forming polymers (27). The presence of a large number of
hydroxyl groups, which form a complex of hydrogen bonds with the hydroxyl group
present in mucin, will result in mucoadhesion. However, it has been already reported
that the time required to completely wash off the NSAID agents like valdecoxib contain-
ing sodium alginate microspheres is 95 min compared to similarly prepared microsphe-
res of naproxen sodium containing alginate (90 min).
All the formulations under storage were analysed for drug content and no signi-
ficant differences in drug content were observed. All the formulations showed less
than 90 % drug content, except formulation NM8 which showed 92.18 % drug content
under both accelerated and room temperature storage conditions (Fig. 7). The degrada-
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Fig. 7. Stability of naproxen sodium microspheres under accelerated conditions and at room tem-
perature (mean ± SD, n = 3). AT – accelerated temperature (40 °C), RT – room temperature, D – days,
M – months.
tion rate constants (kcal) and shelf life (t90) of NM8 at room temperature were 2.46 day–1
and 795.96 days, respectively, which indicates that formulation NM8 has a shelf life of
more than 2 years.
CONCLUSIONS
Data obtained from this study demonstrate that sodium alginate microspheres con-
taining naproxen sodium were successfully prepared, followed by coating with the pH-
-sensitive polymer Eudragit S-100. The study also concluded that naproxen sodium tab-
lets showed total release in 7 h in comparison with sodium alginate microspheres (core
microspheres) that showed complete drug release within 10 h. This suggests that both
naproxen sodium tables and sodium alginate microspheres were unable to target drug
release into the colonic region. Hence, this indicates that there is a need for enteric coat-
ing, i.e., Eudragit S100 coating, on sodium alginate microspheres to target drug release
to the colon. Coated microspheres showed a longer residence time in the colon after re-
moving the Eudragit S100 coating due to better mucoadhesion properties of sodium
alginate. The in vitro release profile revealed that microspheres retard drug release in the
upper part of GIT due to the pH-sensitive polymer coating. Hence, Eudragit S-100 sho-
wed promising drug delivery to the colon.
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Table II. Comparison of different dissolution kinetics models
Formulation
code
Zero-order First-order Higuchi Korsmeyer-Peppas
R2 R2 R2 R2 N
NM 1 0.892 0.986 0.990 0.979 0.50
NM 2 0.896 0.986 0.990 0.976 0.71
NM 3 0.950 0.884 0.988 0.978 0.56
NM 4 0.916 0.976 0.993 0.970 0.67
NM 5 0.951 0.956 0.987 0.984 0.54
NM 6 0.919 0.977 0.980 0.975 0.89
NM 7 0.934 0.957 0.959 0.951 0.92
NM 8 0.949 0.930 0.949 0.958 0.36
NM 9 0.954 0.955 0.956 0.953 0.39
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S A @ E T A K
Alginatne mikrosfere naproksen natrija oblo`ene Eudragitom S-100:
Priprava, optimizacija i in vitro vrednovanje
ANUJ CHAWLA, POOJA SHARMA i PRAVIN PAWAR
Cilj istra`ivanja bila je ciljana isporuka naproksen natrija koriste}i natrijev alginat i
Eudragit S-100 kao mukoadhezivne, odnosno pH-osjetljive polimere. Jezgra mikrosfera
od alginata pripravljena je modificiranom metodom emulgiranja te umre`avanjem po-
mo}u otopine CaCl2. Sljede}i korak u pripravi mikrosfera bilo je oblaganje s pH osjetlji-
vim polimerom Eudragit S-100 (2,5 ili 5 %) ~ime je sprije~eno osloba|anje lijeka u gornjem
dijelu gastrointestinalnog trakta. Mikrosfere su okarakterizirane FT-IR spektroskopijom,
difrakcijom rendgenskih zraka, diferencijalnom pretra`nom kalorimetrijom i pretra`nom
elektronskom mikroskopijom. Nadalje, analizirana je veli~ina ~estica, koli~ina ukloplje-
nog lijeka, mukoadhezivna svojstva in vitro te osloba|anje lijeka in vitro u razli~itim si-
muliranim gastri~nim fluidima. Testovi stabilnosti optimiziranih pripravaka pra}eni su
tijekom 6 mjeseci prema smjernicama ICH. SEM snimke otkrile su da je povr{ina jezgre
mikro~estica neravna, dok je povr{ina oblo`enih mikrosfera glatka. Jezgre mikrosfera imale
su ja~e izra`ena mukoadhezivna svojstva nego oblo`ene mikrosfere na testovima prove-
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denim na svje`e izrezanim dijelovima debelog crijeva koze. Iz optimiziranih neoblo`enih i
oblo`enih mikrosfera osloba|a se 98.42 ± 0.96, odnosno 95.58 ± 0.74 % lijeka. Osloba|anje
lijeka iz svih formulacija slijedilo je kinetiku po Higuchiju. Osloba|anje iz oblo`enih mi-
krosfera slijedilo je Korsmeyer-Peppasovu jednad`bu i kinetiku po Ficku. Studije stabil-
nosti pokazale su minimalnu razgradnju, te prihvatljivu stabilnost tijekom dvogodi{njeg
skladi{tenja.
Keywords: specifi~na isporuka u kolonu, Eudragit S-100, mikrosfere, naproksen natrij, natrijev alginat
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